Payment overview · 2025
General Payments
$432.54
18 reported records · 10 companies
Healthcare provider profile · identity verified
Meyer E Cohen, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BOCA RATON, FL · NPI 1912017591
Verified facts
What the public records show
CMS Open Payments records show Meyer E Cohen, M.D. received $432.54 in general payments during 2025 across 18 reported records.
Novartis Pharmaceuticals Corporation accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $69.95 | 16.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.83 | 15.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.01 | 15.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.21 | 14.4% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $47.80 | 11.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.51 | 6.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $25.50 | 5.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.60 | 5.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.68 | 4.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.45 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $432.54 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $69.95 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.21 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $47.31 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.31 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $38.67 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.17 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.51 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.51 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $25.50 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $25.50 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 91 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
79 | 22 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 308 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 259 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 248 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 233 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 142 | 36 |
| Losartan Potassium | Losartan Potassium | 137 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 119 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 37 |
| Alprazolam | Alprazolam | 112 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 42 |
| Omeprazole | Omeprazole | 110 | 35 |
| Ezetimibe | Ezetimibe | 102 | 33 |
| Lisinopril | Lisinopril | 96 | 28 |
| Eliquis | Apixaban | 91 | 23 |
| Potassium Chloride | Potassium Chloride | 91 | 31 |
| Metformin Hcl | Metformin Hcl | 81 | 24 |
| Synthroid | Levothyroxine Sodium | 79 | 22 |
| Ozempic | Semaglutide | 78 | 15 |
| Methylprednisolone | Methylprednisolone | 75 | 60 |
| Donepezil Hcl | Donepezil Hcl | 73 | 18 |
| Simvastatin | Simvastatin | 72 | 21 |
| Furosemide | Furosemide | 66 | 23 |
| Allopurinol | Allopurinol | 65 | 18 |
| Gabapentin | Gabapentin | 65 | 17 |
| Sertraline Hcl | Sertraline Hcl | 63 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 17 |
| Irbesartan | Irbesartan | 56 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 14 |
| Azithromycin | Azithromycin | 52 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 17 |
| Tramadol Hcl | Tramadol Hcl | 47 | 19 |
| Finasteride | Finasteride | 44 | 12 |
| Montelukast Sodium | Montelukast Sodium | 44 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 43 | 34 |
| Trazodone Hcl | Trazodone Hcl | 43 | 18 |
| Xarelto | Rivaroxaban | 43 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 32 |
| Clonazepam | Clonazepam | 41 | 13 |
| Atenolol | Atenolol | 39 | suppressed |
| Ramipril | Ramipril | 35 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Famotidine | Famotidine | 33 | 11 |
| Ondansetron Odt | Ondansetron | 32 | 22 |
| Carvedilol | Carvedilol | 30 | suppressed |
| Ketoconazole | Ketoconazole | 30 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 22 |
| Spironolactone | Spironolactone | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | suppressed |
| Prednisone | Prednisone | 25 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 16 |
| Clonidine | Clonidine | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 16 |
| Lagevrio (Eua) | Molnupiravir | 22 | 22 |
| Meloxicam | Meloxicam | 22 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 16 |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | 12 |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Lovastatin | Lovastatin | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 12 |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | 11 |
| Celecoxib | Celecoxib | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $432.54 · 18 records | Novartis Pharmaceuticals Corporation | ABRYSVO, AREXVY, COMIRNATY, ELIQUIS, ENTRESTO, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, Veozah, Wegovy, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error